Change of 6.39% for Aclaris Therapeutics Inc (NASDAQ:ACRS)’s shares shorted was showed. In December was published ACRS’s total 4.34 million shares shorted by FINRA. The 4.64M previous shares are down with 6.39%. Aclaris Therapeutics Inc (NASDAQ:ACRS) has 339,400 shares average volume. It’ll cost 13 days for ACRS to restore its previous position. Float short on Aclaris Therapeutics Inc is 17.84%.
The stock decreased 3.84% or $0.33 during the last trading session, hitting $8.26.Currently Aclaris Therapeutics, Inc. is downtrending after 42.52% change in last December 8, 2017. ACRS has also 286,837 shares volume. ACRS underperformed by 58.14% the S&P 500.
Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.The company has $338.13 million market cap. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor.Last it reported negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.
For more Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news released briefly go to: Globenewswire.com, Benzinga.com, Nasdaq.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan – GlobeNewswire” released on October 15, 2018, “Benzinga’s Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure – Benzinga” on May 08, 2018, “Aclaris’ Alopecia Candidate Gets Fast Track Designation – Nasdaq” with a publish date: July 10, 2018, “Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug – Nasdaq” and the last “Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata – GlobeNewswire” with publication date: June 28, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.